Peroxisome proliferator-activated receptors (PPARs) are members of the nuclear receptor family. After activation by specific ligands, they regulate the transcription of genes involved in lipid and lipoprotein metabolism, glucose and energy homeostasis, as well as cellular differentiation. Recent studies have identified expression of the three PPARs in all cells of the arterial wall, where they control cholesterol homeostasis as well as the inflammatory response and, as a consequence, modulate atherogenesis. More generally, PPARs influence cell proliferation as well as the immune and inflammatory response in different tissues and cells. In this review, we will summarize the evidence indicating that PPARs are modulators of the inflammatory response with potential therapeutic applications not only in atherosclerosis, but potentially also in other inflammation-related diseases, such as hepatic inflammation and inflammatory bowel disease.
Introduction
The peroxisome proliferator-activated receptor (PPAR) family consists of three different genes, PPARa, PPARb/d and PPARg. Although all three PPARs are widely expressed, their relative levels differ greatly between tissues in reflection of their distinct biological functions. PPARa is highly expressed in the liver, skeletal muscle and heart. PPARg is predominantly detected in adipose tissue, but is also present at high levels in intestine, breast tissue, etc. Finally, PPARb/d is ubiquitously expressed with highest levels in skin and skeletal muscle. All PPARs are present in cells of the vascular wall and the immune system. PPARs are activated by natural ligands such as fatty acids, eicosanoids and oxidized fatty acids and by pharmacological compounds. The lipid-lowering fibrates and the antidiabetic glitazones are synthetic ligands for PPARa and PPARg, respectively. 1 PPARs influence gene expression either through direct promoter-binding and transcriptional modulation of target genes (termed 'transactivation') or through indirect interference with other transcription factor pathways leading in most cases to transcription inhibition (termed 'transrepression') ( Figure 1 ). PPARs regulate transcription of target genes involved in lipid and lipoprotein metabolism, glucose homeostasis and cell differentiation (particularly adipogenesis). Moreover, PPARs inhibit the activation of certain inflammatory response genes acting as transrepressors. 1 The central role of PPARs as transcriptional mediators in the regulation of important metabolic process that influence cardiovascular risk, namely obesity and lipid metabolism, has been recently reviewed. 2 In this article we will focus on the functions of PPARs in inflammation and associated disorders.
PPARs and inflammation control
The first evidence for a potential role for PPARs in inflammation came from the observation that PPARadeficient mice showed a prolonged inflammation in response to the proinflammatory leukotriene B4 (LTB4). Several recent studies aimed to delineate the cellular and molecular mechanisms by which PPARa modulates the inflammatory response. Activated PPARa inhibits the production of inflammatory response markers, such as endothelin-1 intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1) in endothelial cells and tissue factor, matrix metalloproteinase (MMP)-9 and tumor necrosis factor alpha (TNFa) in macrophages (reviewed in
. In human aortic smooth muscle cells (SMC), PPARa activation by fibrates inhibits interleukin-1 (IL-1)-stimulated IL-6 secretion and 6-keto platelet growth factor (PGF) 1a production by decreasing IL-6 and cyclooxygenase (COX)2 gene transcription. 4 Furthermore, aortic explants from PPARa-deficient mice displayed an exacerbated response to inflammatory stimuli such as lipopolysaccharide (LPS), as demonstrated by increased IL-6 secretion. In addition, splenocytes isolated from PPARa-deficient mice produced more IL-6 and IL-12 in response to LPS than cells from wild-type mice. 5 Taken together, these observations provide evidence that PPARa plays role in the inflammatory response in different cell types. Increasing information is beginning to emerge regarding a role for PPARb/d in the control of inflammation, especially in skin keratinocytes (Figure 2 ). Treatment of PPARb/d wild-type mice with the synthetic PPARb/d activator sulindac resulted in lower skin inflammation induced by phorbolesters, whereas the inflammatory response was more pronounced in PPARb/d-deficient mice. 6 Furthermore, keratinocytes derived from PPARb/d-deficient mice exhibit severely delayed differentiation induced by inflammatory cytokines and are more sensitive to TNFa-induced apoptosis. 7 The role of PPARg in inflammation is more controversial due to the fact that PPARg-deficient mice are not viable and genetic evidence is thus difficult to obtain. However, several laboratories have now established tissue-specific PPARgdeficient mice and the first studies using these models are now appearing. PPARg ligands inhibit TNFa, IL-6 and IL-1b expression in monocytes, interferon (IFN)g-induced expression of the T-cell-specific CXC-chemokines, IFNg-inducible protein 10 (IP-10), Mig, I-TAC, and cell-adhesion molecules, such as VCAM-1, ICAM-1, and endothelin-1 in endothelial cells. 8 In macrophages, PPARg ligands repress inducible nitric oxyde synthase (iNOS) and MMP-9 expression 8 and increase the production of the IL-1 receptor antagonist. 9 In murine splenocytes, PPARg activation leads to a decreased IFNg and IL-12 production. 10 Considering the critical role of these celladhesion and chemoattractant molecules in the recruitment of cells of the immune system, including monocytes and leukocytes, to the site of inflammation, downregulation of these genes by PPARg ligands may prevent the development of inflammatory diseases, such as atherosclerosis. In different mouse models of atherosclerosis, glitazones reduce atherosclerosis associated with decreased TNFa and MMP-9 expression in the aortic root. Finally, in an in vivo model of inflammation and hyperalgesia induced by intraplantar carrageenan injection in rats, specific PPARa and PPARg ligands reduce edema formation. 11 However, most pathophysiological evidence for an antiinflammatory action of PPARg comes from pharmacological approaches. Certain anti-inflammatory properties of PPARg were also observed in PPARg-deficient embryonic stem cellderived macrophages. Thus, it has been suggested that glitazones and natural PPARg ligands exert anti-inflammatory activities in a PPARg-dependent and -independent manner. 12 Since most anti-inflammatory effects of these compounds are observed at extremely high concentrations, it is possible that 'spill-over' activation of the other PPARs expressed in these cells may explain the observed antiinflammatory activities. In addition, certain natural PPARg ligands exert direct, PPARg-independent anti-inflammatory 
PPARs and the immune response
PPARs are expressed in immune cells 13, 14 where they modulate the expression of cytokines and costimulatory molecules. In dendritic cells (DC), the major antigen-presenting cells capable of inducing T-cell-mediated immune responses against a wide range of antigens, PPARg activators reduce the secretion of IL-12, 13,14 a proinflammatory cytokine playing a key role in atherogenesis and the polarization of the immune response toward T H 1. 15 PPARg activation also affects the surface expression of costimulatory molecules, such as CD80 and CD86, and the synthesis of chemokines involved in the recruitment of T H 1 cells, including RANTES and IP-10.
14 In addition, PPARg ligands reduce IL-10 secretion and inhibit the expression of the chemokine EB1 ligand and CCR7, both playing a pivotal role in DC migration to the lymph nodes. 16 These effects are accompained by downregulation of LPSinduced nuclear localization of the RelB protein, a transcription factor of the NF-kB family controlling DC differentiation and function. These effects of PPARg ligands in DCs can drive the local immune response by favoring the differentiation of T H 2 cells, thus orienting the immune response toward a humoral response. In T cells, PPARg activators reduce the synthesis of cytokines, including IFNg and TNFa, 17 and exert antiproliferative effects. 18 PPARg activation leads to a decreased production of IL-2 by negatively interfering with the T-cellspecific transcription factor NFAT. 19 Inhibition of inflammatory cytokine production and proliferation in T cells is correlated with the suppression of activated transcription factor AP-1 and NF-kB. 20 Moreover, PPARg ligands can also control major histocompatibility complex class (MHC) IImediated T-cell activation by inhibiting IFNg-induced MHC-II expression in vascular cells. 21 In contrast, the actions of PPARa in T cells are less well documented. In human T cells, PPARa activators reduce the secretion of IFNg, TNFa and IL-2. 17 Decreased secretion of IL-2 occurred through NF-kB transrepression in murine T and B lymphocytes. 22 In addition, T cells isolated from PPARadeficient mice produce higher levels of IFNg than T cells from wild-type mice, indicating a role for endogenous PPARa protein in lymphocyte function. 22 Altogether, these data suggest functions for PPARs extending to cells of the immune system with potential profound impact on the immune response.
PPARa and hepatic inflammation
PPARa is highly expressed in the liver, where it has initially been thought to regulate mainly genes involved in fatty acid b-oxidation. 1 More recently, additional hepatic functions for PPARa have been identified. In primary human hepatocytes and hepatoma cells, PPARa activators suppress IL-1-induced C-reactive protein (CRP) and IL-6-induced fibrinogen expression, the major acute-phase response (APR) proteins in humans, 23 whose plasma concentrations are elevated not only in acute but also in chronic inflammatory states. This anti-inflammatory action of PPARa is not restricted to these genes, but applies more generally to other APR genes, such as serum amyloid A (SAA) and fibrinogen-a and -b. 24 PPARa activation leads to a reduction in the formation of nuclear C/EBPbBp50-NFkB complexes, and thereby reduces CRP promoter activation. Fibrinogen-b, a procoagulant factor, is repressed by fibrates acting via PPARa that interferes negatively with the C/EBPb pathway through promoter-specific titration of the coactivator GRIP1/ TIF2. 24 Moreover, PPARa increases IkBa expression, thus preventing nuclear p50/p65 NF-kB translocation and arresting their nuclear transcriptional activity. Moreover, chronic treatment with fibrates decreases hepatic C/EBPb and p50-NF-kB protein expression in mice in a PPARadependent manner. 23 This latter effect likely contributes to the generalized anti-inflammatory effects of fibrates on the expression of a wide range of APR genes containing response elements for these transcription factors in their promoters. These findings identify a novel molecular mechanism of negative gene regulation by PPARa and reveal a direct implication for PPARa in the modulation of the inflammatory gene response in the liver.
PPARg and inflammatory bowel diseases
As the expression levels of PPARg in the colon and small intestine of human and rodents are higher than those observed in other organs, it is not surprising that several studies have focused on a potential role for this transcription factor in intestinal inflammation.
Using an in vivo model of intestinal inflammation induced by ischemia-reperfusion, rosiglitazone treatment was shown to protect against local and remote injury in wildtype mice whereas more severe injury was observed in PPARg-deficient mice. 25 PPARg activation resulted in the downregulation of ICAM-1 and TNFa expression in intestinal endothelium. Interestingly, PPARg heterozygous deficient mice are more susceptible to inflammation in the 2,4,6-trinitrobenzen sulfonic acid-induced colitis model. 26 Administration of PPARg ligands decreased TNFa and IL-1b gene expression and myeloperoxidase activity, and reduced NF-kB DNA binding activity in the colon. Taken together, these data indicate a potentially important anti-inflammatory role for PPARg in the gastrointestinal tract.
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PPARs: from basic science to clinical applications
Clinical indications regarding a role for PPAR agonists in inflammation control comes from clinical trials using synthetic agonists, the fibrates and glitazones. The influence of PPARa activators on plasma cytokine levels as well as on acute-phase proteins has been determined in patients with angiographically established atherosclerosis. 4 Fenofibrate treatment decreased the circulating levels of IL-6 and lowered the plasma levels of CRP and fibrinogen in patients with coronary artery disease. 4 In addition, fenofibrate significantly reduced plasma IFNg and TNFa levels in patients with type IIb hyperlipoproteinemia. 27 Similar findings were reported with bezafibrate in hypertriglyceridemic patients. 28 A recent study reported anti-inflammatory actions of glitazones also. Treatment of type II diabetes mellitus patients with rosiglitazone resulted in a reduction of serum concentrations of CRP and MMP-9 and white blood cell count. 29 Interestingly, in patients with moderate active ulcerative colitis, 12-week rosiglitazone administration led to a clinical remission in 27% of cases. 30 These reports suggest that treatment with PPAR activators decreases plasma levels of inflammatory markers in patients. However, clinical studies do not allow one to determine whether these effects are direct or indirectly mediated via the improved metabolic control obtained in patients treated with these drugs.
Conclusions
Even though PPARs are master regulators of lipid and lipoprotein metabolism as well as glucose homeostasis, emerging evidence indicates that PPARa and PPARg also improve inflammatory states. Based on these findings, mainly coming from preclinical models, fibrates and glitazones, and possibly mixed PPARa/PPARg ligands, can be expected to have a therapeutic benefit in the treatment of inflammation-related disorders.
